fbpx

Palisade Bio Inc

PALI

$2.49

Closing

▲1.22%

1D

▼-71.86%

YTD

PALI

BBG001SS4KZ8

Exchange

Sector

Market cap

$3.26M

Volume

5,227

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $6.99/month

Market cap

$3.26M

Analysts' Rating

STRONG BUY

Price Target (Mean)

33.75

Total Analysts

2

P/E

Operating Margin

0.00%

Beta

1.38

Revenue Growth

0.00%

52 week high

$22.35

52 week low

$2.19

Div. Yield

%

EPS Growth

-27.67

Company Profile

Palisade Bio, Inc. is a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal diseases. It is engaged in advancing a PALI-2108 for the treatment of IBD, including UC and CD and are researching PALI-1908. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract. UC primarily affects the colon and the rectum. CD can affect any part of the gastrointestinal tract, from the mouth to the anus. PALI-2108 is a prodrug PDE4 inhibitor that operates through a mechanism within colon tissues, targeting the key enzyme phosphodiesterase-4 (PDE4). This enzyme is pivotal in cAMP hydrolysis, and by inhibiting PDE4, intracellular cAMP levels are elevated. This elevation leads to the downregulation of inflammatory cytokines and a reduction in the expression of cell adhesion molecules. By modulating these processes, PALI-2108 prevents the local infiltration and activation of inflammatory cells in the colon tissues.